» Articles » PMID: 21450975

Protective Immunity Against Experimental Pulmonary Cryptococcosis in T Cell-depleted Mice

Overview
Date 2011 Apr 1
PMID 21450975
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Individuals with defects in T cell-mediated immunity (CMI) are highly susceptible to infection with Cryptococcus neoformans. The purpose of these studies was to determine if protection against experimental pulmonary cryptococcosis can be generated in T cell-deficient hosts. BALB/c mice were depleted of CD4⁺and/or CD8⁺ T cells or given an isotype control antibody prior to vaccination with a C. neoformans strain, designated H99γ, previously shown to induce protection against C. neoformans infection in immunocompetent mice. Mice depleted of CD4⁺ or CD8⁺ T cells, but not both subsets, survived an acute pulmonary infection with C. neoformans strain H99γ and a subsequent second challenge with wild-type C. neoformans strain H99. We observed a significant increase in the percentage of CD4⁺ and CD8⁺ T cells expressing the activation marker CD69 in the lungs of mice immunized with C. neoformans strain H99γ prior to a secondary challenge with wild-type cryptococci. CD4⁺ T cells within the lungs of immunized mice also appeared to acquire a predominantly activated effector memory cell phenotype (CD69⁺ CD44⁺ CCR7⁻ CD45RB⁻ CD62L⁻) following a second pulmonary challenge with wild-type C. neoformans, compared to CD4⁺ T cells from naïve mice. Lastly, immunization of immunocompetent mice with C. neoformans strain H99γ prior to depletion of CD4⁺ and/or CD8⁺ T cells resulted in significant protection against a second challenge with wild-type C. neoformans. Our studies demonstrate that protective immunity against pulmonary cryptococcosis can be generated in immunosuppressed hosts, thus supporting the development of cryptococcal vaccines.

Citing Articles

Identification of a protective antigen reveals the trade-off between iron acquisition and antigen exposure in a global fungal pathogen.

Li Y, Pham T, Hipsher K, Lee C, Jiao J, Penninger J Proc Natl Acad Sci U S A. 2025; 122(7):e2420898122.

PMID: 39946532 PMC: 11848283. DOI: 10.1073/pnas.2420898122.


Will the Real Immunogens Please Stand Up: Exploiting the Immunogenic Potential of Cryptococcal Cell Antigens in Fungal Vaccine Development.

Avina S, Pawar S, Rivera A, Xue C J Fungi (Basel). 2024; 10(12).

PMID: 39728336 PMC: 11676676. DOI: 10.3390/jof10120840.


Fungal vaccines and adjuvants: a tool to reveal the interaction between host and fungi.

Wang Z, Shao J Arch Microbiol. 2024; 206(7):293.

PMID: 38850421 DOI: 10.1007/s00203-024-04010-7.


Vaccine Strategies for Cryptococcus neoformans.

Brauer V, Querobino S, Matos G, Dasilva D, Del Poeta M Methods Mol Biol. 2024; 2775():411-422.

PMID: 38758334 DOI: 10.1007/978-1-0716-3722-7_28.


Application of anti-fungal vaccines as a tool against emerging anti-fungal resistance.

Kumar R, Srivastava V Front Fungal Biol. 2023; 4:1241539.

PMID: 37746132 PMC: 10512234. DOI: 10.3389/ffunb.2023.1241539.


References
1.
Collins V, GELLHORN A, TRIMBLE J . The coincidence of cryptococcosis and disease of the reticulo-endothelial and lymphatic systems. Cancer. 1951; 4(4):883-9. DOI: 10.1002/1097-0142(195107)4:4<883::aid-cncr2820040426>3.0.co;2-g. View

2.
KEYE Jr J, Magee W . Fungal diseases in a general hospital; a study of 88 patients. Am J Clin Pathol. 1956; 26(11):1235-53. DOI: 10.1093/ajcp/26.11.1235. View

3.
Wuthrich M, Filutowicz H, Warner T, Deepe Jr G, Klein B . Vaccine immunity to pathogenic fungi overcomes the requirement for CD4 help in exogenous antigen presentation to CD8+ T cells: implications for vaccine development in immune-deficient hosts. J Exp Med. 2003; 197(11):1405-16. PMC: 2193905. DOI: 10.1084/jem.20030109. View

4.
Vivier E, Raulet D, Moretta A, Caligiuri M, Zitvogel L, Lanier L . Innate or adaptive immunity? The example of natural killer cells. Science. 2011; 331(6013):44-9. PMC: 3089969. DOI: 10.1126/science.1198687. View

5.
Saag M, Graybill R, Larsen R, Pappas P, Perfect J, Powderly W . Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis. 2000; 30(4):710-8. DOI: 10.1086/313757. View